Both in vitro and in vivo research of the consequences of rifaximin on commensal flora suggest that rifaximin-resistant organisms have low viability.25,44,45 In summary, this scholarly study shows a robust protective aftereffect of rifaximin against episodes of hepatic encephalopathy. Rifaximin reduces the risk of hospitalization involving hepatic encephalopathy also.1,31.. Nathan M. Bass, M.B., Ch.B., Ph.D., Kevin D. Mullen, M.D., Arun Sanyal, M.D., Fred Poordad, M.D., Man Neff, M.D., Carroll B. Leevy, M.D., Samuel Sigal, M.D., Muhammad Y. Sheikh, M.D., Kimberly Beavers, M.D., Todd Frederick, M.D., Lewis Teperman, M.D., Donald Hillebrand, M.D., Shirley Huang, M.S., Kunal Merchant, Ph.D., Audrey Shaw, Ph.D., Enoch Bortey, Ph.D., and William P.Diluted earnings per share under Generally Accepted Accounting Principles were $0.69, up 50.0 %. Today, Abbott is raising its guidance for full-yr 2008 adjusted income per share to $3.31 – $3.33 from $3.24 – $3.28, excluding specified items. Projected earnings per share under GAAP is $3.23 – $3.25. Worldwide sales elevated 17.6 % to $7.5 billion, including a good 4.7 % effect of exchange rates. Worldwide pharmaceutical sales increased 16.7 % driven by double-digit growth in HUMIRA, TriCor, Niaspan and Kaletra. Global HUMIRA product sales exceeded $1.2 billion; Abbott now expects full-year 2008 global HUMIRA sales greater than $4.4 billion.